ATE399017T1 - Neue angiogenese-inhibitoren basierend auf löslicher hyaluronsäure-bindedomäne des cd44- rezeptors - Google Patents

Neue angiogenese-inhibitoren basierend auf löslicher hyaluronsäure-bindedomäne des cd44- rezeptors

Info

Publication number: ATE399017T1
Authority: AT; Austria
Prior art keywords: hyaluronic acid; receptor; angiogenesis; recombinant; human
Prior art date: 2001-08-24

Application number

AT02760977T

Other languages

English (en)

Inventor

Stroemblad Staffan

Priit Kogerman

Taavi Paell

Original Assignee

Celecure As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-24

Filing date

2002-08-26

Publication date

2008-07-15

2001-08-24 Priority claimed from SE0102823A external-priority patent/SE0102823D0/xx

2002-08-26 Application filed by Celecure As filed Critical Celecure As

2008-07-15 Application granted granted Critical

2008-07-15 Publication of ATE399017T1 publication Critical patent/ATE399017T1/de

Links

101000868273 Homo sapiens CD44 antigen Proteins 0.000 title abstract 8
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title abstract 6
229920002674 hyaluronan Polymers 0.000 title abstract 6
229960003160 hyaluronic acid Drugs 0.000 title abstract 6
229940121369 angiogenesis inhibitor Drugs 0.000 title abstract 2
239000004037 angiogenesis inhibitor Substances 0.000 title abstract 2
102100032912 CD44 antigen Human genes 0.000 abstract 6
230000033115 angiogenesis Effects 0.000 abstract 3
230000004614 tumor growth Effects 0.000 abstract 3
206010027476 Metastases Diseases 0.000 abstract 2
241000699666 Mus <mouse, genus> Species 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 2
230000001772 anti-angiogenic effect Effects 0.000 abstract 2
230000009401 metastasis Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
108010001857 Cell Surface Receptors Proteins 0.000 abstract 1
102000000844 Cell Surface Receptors Human genes 0.000 abstract 1
201000008808 Fibrosarcoma Diseases 0.000 abstract 1
241000699670 Mus sp. Species 0.000 abstract 1
108700020796 Oncogene Proteins 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
230000012292 cell migration Effects 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000002547 new drug Substances 0.000 abstract 1
230000002018 overexpression Effects 0.000 abstract 1
230000035479 physiological effects, processes and functions Effects 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
238000012216 screening Methods 0.000 abstract 1
238000007920 subcutaneous administration Methods 0.000 abstract 1
230000008685 targeting Effects 0.000 abstract 1
210000005167 vascular cell Anatomy 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70585—CD44
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Zoology (AREA)
Oncology (AREA)

AT02760977T 2001-08-24 2002-08-26 Neue angiogenese-inhibitoren basierend auf löslicher hyaluronsäure-bindedomäne des cd44- rezeptors ATE399017T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31497101P	2001-08-24	2001-08-24
SE0102823A SE0102823D0 (sv)	2001-08-24	2001-08-24	New drug

Publications (1)

Publication Number	Publication Date
ATE399017T1 true ATE399017T1 (de)	2008-07-15

Family

ID=26655535

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02760977T ATE399017T1 (de)	2001-08-24	2002-08-26	Neue angiogenese-inhibitoren basierend auf löslicher hyaluronsäure-bindedomäne des cd44- rezeptors

Country Status (12)

Country	Link
US (1)	US20050054593A1 (de)
EP (1)	EP1418931B1 (de)
JP (1)	JP4580646B2 (de)
CN (1)	CN1561223A (de)
AT (1)	ATE399017T1 (de)
AU (1)	AU2002326277B2 (de)
CA (1)	CA2458565A1 (de)
DE (1)	DE60227263D1 (de)
DK (1)	DK1418931T3 (de)
ES (1)	ES2309193T3 (de)
PT (1)	PT1418931E (de)
WO (1)	WO2003018044A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8192744B2 (en) *	2002-08-26	2012-06-05	Ibcc Holding As	Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
US6982298B2 (en)	2003-01-10	2006-01-03	The Cleveland Clinic Foundation	Hydroxyphenyl cross-linked macromolecular network and applications thereof
US8138265B2 (en)	2003-01-10	2012-03-20	The Cleveland Clinic Foundation	Hydroxyphenyl cross-linked macromolecular network and applications thereof
US7465766B2 (en)	2004-01-08	2008-12-16	The Cleveland Clinic Foundation	Hydroxyphenyl cross-linked macromolecular network and applications thereof
US8137688B2 (en)	2003-01-10	2012-03-20	The Cleveland Clinic Foundation	Hydroxyphenyl cross-linked macromolecular network and applications thereof
WO2007149948A2 (en) *	2006-06-20	2007-12-27	The Gov. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services	Compositions and methods for diagnosis and treatment of tumors
US20090060984A1 (en) *	2007-09-05	2009-03-05	John Texter	Anionic surfactants lethal to gram-positive bacteria
EP2249891B1 (de)	2008-02-13	2016-05-25	The Cleveland Clinic Foundation	Molekulare verstärkung von extrazellulärer matrix und anwendungsverfahren
WO2009135029A2 (en)	2008-04-30	2009-11-05	The Cleveland Clinic Foundation	Compositions and methods to treat urinary incontinence
US8313914B2 (en) *	2009-03-06	2012-11-20	Angstrom Pharmaceuticals, Inc.	Compositions and methods for modulation of cell migration
EP2542253A4 (de) *	2010-03-05	2013-08-21	Angstrom Pharmaceuticals Inc	Modulation einer interzellulären signalisierung
CN102429868A (zh) *	2011-12-09	2012-05-02	南开大学	具有肿瘤靶向、体内示踪和治疗作用的脂质体药物组合物及制备方法
WO2015021993A1 (en) *	2013-08-13	2015-02-19	Ibcc Holding As	Pharmacologically active modified sb101 molecules and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5863540A (en) *	1991-03-15	1999-01-26	Duke University	Adhesion molecule
AU5543594A (en) *	1992-10-30	1994-05-24	Duke University	An adhesion molecule
WO1995000851A1 (de) *	1993-06-22	1995-01-05	Boehringer Ingelheim International Gmbh	Verfahren zur diagnose und analyse von tumoren
UA58482C2 (uk) *	1994-06-08	2003-08-15	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
EP1064011A1 (de) *	1998-03-13	2001-01-03	EntreMed, Inc.	Metastatin und hyaluronat bindende proteine sowie methoden zur verwendung
US6022952A (en) *	1998-04-01	2000-02-08	University Of Alberta	Compositions and methods for protein secretion

2002
- 2002-08-26 WO PCT/SE2002/001531 patent/WO2003018044A1/en active Application Filing
- 2002-08-26 JP JP2003522561A patent/JP4580646B2/ja not_active Expired - Fee Related
- 2002-08-26 ES ES02760977T patent/ES2309193T3/es not_active Expired - Lifetime
- 2002-08-26 AT AT02760977T patent/ATE399017T1/de not_active IP Right Cessation
- 2002-08-26 EP EP02760977A patent/EP1418931B1/de not_active Expired - Lifetime
- 2002-08-26 DK DK02760977T patent/DK1418931T3/da active
- 2002-08-26 US US10/487,620 patent/US20050054593A1/en not_active Abandoned
- 2002-08-26 CN CNA028192753A patent/CN1561223A/zh active Pending
- 2002-08-26 DE DE60227263T patent/DE60227263D1/de not_active Expired - Lifetime
- 2002-08-26 AU AU2002326277A patent/AU2002326277B2/en not_active Ceased
- 2002-08-26 CA CA002458565A patent/CA2458565A1/en not_active Abandoned
- 2002-08-26 PT PT02760977T patent/PT1418931E/pt unknown

Also Published As

Publication number	Publication date
JP4580646B2 (ja)	2010-11-17
CN1561223A (zh)	2005-01-05
ES2309193T3 (es)	2008-12-16
CA2458565A1 (en)	2003-03-06
WO2003018044A8 (en)	2004-06-24
EP1418931B1 (de)	2008-06-25
DE60227263D1 (de)	2008-08-07
US20050054593A1 (en)	2005-03-10
PT1418931E (pt)	2008-10-03
AU2002326277B2 (en)	2007-10-04
EP1418931A1 (de)	2004-05-19
DK1418931T3 (da)	2008-11-03
WO2003018044A1 (en)	2003-03-06
JP2005525995A (ja)	2005-09-02

Legal Events

Date

Code

Title

Description

2009-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1418931

Country of ref document: EP

2011-05-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
Kruger et al.	2014	Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers
DE60227263D1 (de)	2008-08-07	Neue angiogenese-inhibitoren basierend auf löslicher hyaluronsäure-bindedomäne des cd44-rezeptors
El-Tanani et al.	2006	The regulation and role of osteopontin in malignant transformation and cancer
Naor et al.	2009	Involvement of CD44, a molecule with a thousand faces, in cancer dissemination
Sironen et al.	2011	Hyaluronan in human malignancies
Castañeda-Gill et al.	2016	Antiangiogenic mechanisms and factors in breast cancer treatment
Destouches et al.	2012	Multivalent pseudopeptides targeting cell surface nucleoproteins inhibit cancer cell invasion through tissue inhibitor of metalloproteinases 3 (TIMP-3) release
IL149922A (en)	2013-09-30	Tweak receptor antagonist for use in regulating the angiogenesis process, a nucleic acid encoded by the antagonist, expression and host cells that contain the expression carrier and the antagonist to produce the antagonist
Hadfield et al.	2008	HtrA1 inhibits mineral deposition by osteoblasts: requirement for the protease and PDZ domains
ATE330967T1 (de)	2006-07-15	An her2 bindende peptidverbindungen
WO1999022773A3 (en)	1999-10-14	Sequences for targeting metastatic cells
Delord et al.	2005	Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma
ATE354372T1 (de)	2007-03-15	Verwendung von mif-antagonisten zur krebstherapie
WO2003013537A3 (en)	2003-09-25	Irinotecan for treatment of cancer
NO20055209D0 (no)	2005-11-04	Peptabody for cancerbehandling
Jeong et al.	2008	Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells
Zafiropoulos et al.	2008	Decorin-induced growth inhibition is overcome through protracted expression and activation of epidermal growth factor receptors in osteosarcoma cells
Nakajima et al.	2020	Autocrine motility factor and its receptor expression in musculoskeletal tumors
Baruffi et al.	2001	Aneurysmal bone cyst with chromosomal changes involving 7q and 16p
RS20050577A (en)	2007-09-21	Compositions and methods for treating cancer using igsf9 and liv-1
Li et al.	2023	Prospect of targeting lysine methyltransferase NSD3 for tumor therapy
ATE230414T1 (de)	2003-01-15	Mimetika von beta-faltblatt und verfahren zur verwendung davon
HK1052026A1 (en)	2003-08-29	Human enzymes of the metalloprotease family
Wang et al.	2011	Periostin: a putative mediator involved in tumour resistance to anti‐angiogenic therapy?
Morozevich et al.	2008	Implication of α 5 β 1 integrin in invasion of drug-resistant MCF-7/ADR breast carcinoma cells: a role for MMP-2 collagenase